
Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug
New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.







